市场调查报告书
商品编码
1518360
血糖监测设备市场:依产品类型、糖尿病类型、最终用户划分 - 到 2030 年的全球预测Blood Glucose Monitoring Devices Market by Product (Self-monitoring {Glucometer, Test Strips, Lancets}, Continuous Glucose Monitoring {Sensors, Receiver, Transmitter}), Diabetes Type, End User (Self/Home Care, Hospital, Clinic) - Global Forecast to 2030 |
血糖监测设备市场预计到2030年将达到217.1亿美元,2023年至2030年的复合年增长率为7.5%。
经过全面的一手和二手研究以及对市场情景的详细分析,该报告包括对主要市场驱动因素、限制因素、机会和课题的分析。这个市场的驱动因素包括糖尿病盛行率上升、越来越多的人过着不健康和久坐的生活方式,以及糖尿病治疗的产品创新。然而,保险范围和报销的不确定性以及产品召回正在限制市场成长。
此外,新兴国家对非侵入性血糖监测设备的需求不断增长,人们对糖尿病健康的认识不断提高,预计将为该市场的参与者提供巨大的成长机会。然而,大量未确诊的糖尿病患者和连续血糖监测设备的高成本是影响市场成长的主要课题。
依产品划分,自我血糖监测设备预计将在 2023 年占据血糖监测设备市场的最大占有率。该细分市场的巨大市场占有率归因于 2 型糖尿病的高盛行率、对血糖监测设备中使用的试纸的持续需求以及人们对糖尿病自我管理的认识不断增强等因素。
依糖尿病类型划分,预计 2023 年 2 型糖尿病将占据血糖监测设备市场的最大占有率。该细分市场的巨大市场占有率归因于越来越多的人过着不健康的生活方式,缺乏体力活动,导致 2 型糖尿病的盛行率不断上升。
从最终用户来看,预计到 2023 年,自我照护/居家照护领域将占据血糖监测设备市场的最大占有率。由于使用血糖监测设备进行糖尿病自我管理的患者人数较多,且具有便利性和成本效益等优点,因此该细分市场拥有很大的市场占有率。
到 2023 年,北美预计将占据血糖监测设备市场的最大占有率,其次是欧洲和亚太地区。北美市场规模之大得益于糖尿病管理意识高、连续血糖监测等新技术采用率高以及该地区人口购买力高。
Blood Glucose Monitoring Devices Market Size, Share, Forecast, & Trends Analysis by Product (Self-monitoring {Glucometer, Test Strips, Lancets}, Continuous Glucose Monitoring {Sensors, Transmitter}), Diabetes Type, End User- Global Forecast to 2030
The blood glucose monitoring devices market is projected to reach $21.71 billion by 2030, at a CAGR of 7.5% from 2023 to 2030.
Following comprehensive primary and secondary research and an in-depth analysis of the market scenario, this report provides an analysis of the key market drivers, restraints, opportunities, and challenges. This market is driven by the rising prevalence of diabetes, the increasing number of people living unhealthy & sedentary lifestyles, and product innovations in diabetes care. However, insurance coverage and reimbursement uncertainties and product recalls restrain the growth of this market.
Furthermore, the growing demand for non-invasive glucose monitoring devices and increasing awareness regarding diabetic health in developing countries are expected to generate significant growth opportunities for the players in this market. However, the large number of people living with undiagnosed diabetes and the high costs of continuous glucose monitoring devices are major challenges impacting market growth.
Based on product, in 2023, the self-monitoring devices segment is expected to account for the largest share of the blood glucose monitoring devices market. The large market share of this segment is attributed to factors such as the high prevalence of Type-2 diabetes, the recurring demand for test strips used with blood glucose monitoring devices, and increased awareness about diabetes self-management.
Based on diabetes type, in 2023, the Type-2 diabetes segment is expected to account for the largest share of the blood glucose monitoring devices market. The large market share of this segment is attributed to the increased prevalence of Type-2 diabetes due to the increasing number of people living unhealthy lifestyles without physical activity.
Based on end user, in 2023, the self/home care segment is expected to account for the largest share of the blood glucose monitoring devices market. The large market share of this segment is attributed to the large patient population utilizing blood glucose monitoring devices for the self-management of diabetes due to their advantages, such as convenience and cost-effectiveness.
In 2023, North America is expected to account for the largest share of the blood glucose monitoring devices market, followed by Europe and Asia-Pacific. North America's large market is attributed to the high awareness regarding diabetes management, high adoption of newer technologies such as continuous glucose monitoring, and higher purchasing power of the population in the region.
The key players operating in the blood glucose monitoring devices market are Abbott Laboratories (U.S.), Ascensia Diabetes Care Holdings AG (a subsidiary of PHC Holdings Corporation) (Switzerland), Becton, Dickinson and Company (U.S.), DexCom, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), LifeScan IP Holdings, LLC (a subsidiary of Platinum Equity, LLC, U.S.) (Switzerland), Medtronic plc (Ireland), Ypsomed Holding AG (Switzerland), B. Braun Melsungen AG (Germany), Nipro Corporation (Japan), ARKRAY, Inc. (U.S.), Prodigy Diabetes Care, LLC (U.S.), ACON Laboratories, Inc. (U.S.), and Nova Biomedical Corporation (U.S.).
Blood Glucose Monitoring Devices Market Assessment-by Product
Note: Other devices & accessories include hemoglobin A1c testing kits and non-invasive blood glucose monitoring devices.
Blood Glucose Monitoring Devices Market Assessment-by Diabetes Type
Blood Glucose Monitoring Devices Market Assessment-by End User
Note: Other end users include physician offices, ambulatory care settings, and diagnostics labs.
Blood Glucose Monitoring Devices Market Assessment-by Geography